Tagged with BIOTEC

Singapore Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5 years. Here, three key stakeholders from government, academia, and industry weigh in on what Singapore’s current performance and future potential as an innovation hub, translating its…

Hong Kong With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs to IPO, we look back at a stellar 2020 for the Exchange and what the recent appointment of a new CEO – the first foreign appointment in its history – means for the…

Singapore Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies have greater access to funds, both from state actors as well as via private equity and public listings, but barriers…

China Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want…

Switzerland Dr Michael Bauer, a Novartis early development veteran, now serves as CEO of Basel-based Cellestia. Here, Bauer explains why Cellestia’s unique transcription factor targeting molecule potentially represents a breakthrough in cancer research, the ways in which the firm’s funding strategy has evolved, and how its future growth trajectory might look.…

Switzerland Fabian Gerber of SIX Swiss Exchange, Switzerland’s principal stock exchange, outlines the importance of life sciences companies to the exchange, representing over a third of total market capitalization with the presence of Roche, Novartis, Lonza and many others; explains why biotech companies are choosing to go public at later stages…

Switzerland Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the new generation of obesity treatments coming from Big Pharma. Moreover, he discusses EraCal’s development strategy and the Swiss biotech ecosystem.…

China The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.   How Hong Kong can cement its position as a biotech listing hub (SCMP) https://www.scmp.com/comment/opinion/article/3134767/how-hong-kong-can-cement-its-position-biotech-listing-hub To maintain its growth and…

Singapore Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and rich pipeline of clinical assets in global development.   As we are able to now understand biological systems much better…

Japan Toshio Fujimoto, MD, MBA, the General Manager of Shonan Health Innovation Park examines why Japan – despite being well established as one of the world’s most innovative and technologically advanced countries – has lagged behind in terms of VC funding, especially in the life sciences and how this can be…

Singapore Cerecin’s Charles Stacey outlines the company’s progress in expanding its lead asset into migraine and infantile spasms, how its funding strategy has evolved, why Singapore is still a logical base, and how broader developments in the CNS landscape stand to benefit all stakeholders.   Moving to Singapore was a good…

China Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player in the bispecific antibody field.   The Series C financing round means that the company has raised over USD 220…